Premium
Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients
Author(s) -
Farias Eduardo,
Ranuncolo Stella,
Cresta Carlos,
Specterman Sergio,
Armanasco Eduardo,
Varela Mirta,
Lastiri José,
Pallotta María Guadalupe,
Bal de Kier Joffe Elisa,
Puricelli Lydia
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/1097-0215(20000720)89:4<389::aid-ijc12>3.0.co;2-j
Subject(s) - breast cancer , lung cancer , medicine , pathology , cancer , gastroenterology , population , zymography , lung , colorectal cancer , metastasis , matrix metalloproteinase , environmental health
Matrix metalloproteinases (MMP) have been implicated in tumor invasion and metastasis. We verified, by gelatin zymography, MMP activity in the euglobulin plasma fraction of 82 healthy controls, 66 patients with benign diseases and 149 patients with breast, lung, colon or brain cancer. The euglobulin fractions assayed showed 4 gelatinolytic bands of 62, 92, 120 and 200 kDa. The median (Md) value for 92 kDa‐MMP activity was significantly increased in breast (Md 1.34 arbitrary units [AU]/ml plasma, range 0.0–7.2) and lung cancer patients (Md 1.43 AU/ml, range 0.0–3.6) compared with the controls (Md 0.48 AU/ml, range 0.0–1.8). Patients with colon cancer or gliomas presented values of MMP‐9 similar to those of the healthy population. Multivariate analysis indicated that plasma MMP‐9 activity was not predicted by the known clinicopathological parameters such as age, stage, tumor size, number of positive lymph nodes, histologic grade, histologic type, nuclear grade or mitotic index. Lung cancer patients also presented high values of MMP‐9 (Md 1.43, range 0.0–3.6 [n = 26]), without association with tumor stage or histologic type. The levels of 92 kDa‐MMP activity in the plasma euglobulin fraction could be a potentially useful tumor marker in breast and lung cancer. Int. J. Cancer 89:389–394, 2000. © 2000 Wiley‐Liss, Inc.